198 related articles for article (PubMed ID: 1487408)
21. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
22. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study.
Pollera CF; Ceribelli A; Crecco M; Calabresi F
Ann Oncol; 1994 Feb; 5(2):182-4. PubMed ID: 8186164
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
24. Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
[TBL] [Abstract][Full Text] [Related]
25. [An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Fukuoka M; Noda K; Hasegawa K; Nakajima H; Furuse K; Hirabayashi K; Hasegawa K; Ogura T; Niitani H; Taguchi T
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1813-24. PubMed ID: 8937492
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
Penz M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Lenauer A; Depisch D; Krauss G; Schneeweiss B; Scheithauer W
Ann Oncol; 2001 Feb; 12(2):183-6. PubMed ID: 11300321
[TBL] [Abstract][Full Text] [Related]
27. Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study.
Pollera CF; Ceribelli A; Crecco M; Calabresi F
Invest New Drugs; 1994; 12(2):111-9. PubMed ID: 7860227
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
Wolff RA; Evans DB; Gravel DM; Lenzi R; Pisters PW; Lee JE; Janjan NA; Charnsangavej C; Abbruzzese JL
Clin Cancer Res; 2001 Aug; 7(8):2246-53. PubMed ID: 11489798
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA
Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024
[TBL] [Abstract][Full Text] [Related]
30. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Meyer F; Lueck A; Hribaschek A; Lippert H; Ridwelski K
Chemotherapy; 2004 Dec; 50(6):289-96. PubMed ID: 15608445
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
Tse AN; Wu N; Patel D; Haviland D; Kemeny N
Cancer Chemother Pharmacol; 2009 Oct; 64(5):935-44. PubMed ID: 19221752
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.
Eckel F; Schmelz R; Erdmann J; Mayr M; Lersch C
Cancer Invest; 2003; 21(5):690-4. PubMed ID: 14628426
[TBL] [Abstract][Full Text] [Related]
34. Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
Mané JM; Sancho A; Muñoz A; Rubio I; Fernández R; Carrera S; Fuente N; Ballesteros D; Casas R; Marrodán I; Mielgo X; López-Vivanco G
Tumori; 2010; 96(3):405-10. PubMed ID: 20845800
[TBL] [Abstract][Full Text] [Related]
35. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Catimel G; Vermorken JB; Clavel M; de Mulder P; Judson I; Sessa C; Piccart M; Bruntsch U; Verweij J; Wanders J
Ann Oncol; 1994 Jul; 5(6):543-7. PubMed ID: 7918127
[TBL] [Abstract][Full Text] [Related]
37. [Phase II studies of gemcitabine for non-small cell lung cancer in Japan].
Asai G; Fukuoka M
Gan To Kagaku Ryoho; 1999 Jun; 26(7):884-9. PubMed ID: 10396314
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer.
Cho KH; Song YB; Choi IS; Cho EH; Choi JW; Ahn YM; Roh YH; Nam SH; Kim BS
Jpn J Clin Oncol; 2006 Jan; 36(1):50-4. PubMed ID: 16418187
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
[TBL] [Abstract][Full Text] [Related]
40. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Takada M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Fukuoka M
Cancer Chemother Pharmacol; 1998; 41(3):217-22. PubMed ID: 9443638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]